title: Prevalence of hypothyroidism in Finland--a nationwide prescription study.
abstract: OBJECTIVE
  The aim of this study was to estimate the 1-year prevalence of levothyroxine-treated hypothyroidism in Finland.
  
  
  METHODS
  Data on all individuals who had regularly purchased levothyroxine sodium tablets during 2007 were retrieved from the nationwide Finnish Drug Prescription Database. The prevalence rates and 95% confidence intervals were calculated per 100 individuals assuming a Poisson distribution.
  
  
  RESULTS
  In total, 189,027 individuals (84% female) were identified as using levothyroxine tablets, which translated into a 1-year prevalence of hypothyroidism of 3.6%. The disease was notably more common in females (5.9%) than in males (1.2%), with a gender prevalence rate ratio (PRR) of 4.5. Prevalence increased with age. A comparison of five university hospital districts revealed that the prevalence rates were fairly stable regionally, with the lowest rate being 3.1% and the highest 4.4%; the regional PRR was 1.3.
  
  
  CONCLUSIONS
  To the best of our knowledge, this nationwide prescription study includes the largest population of reported levothyroxine users to date. This comprehensive data justifies estimating the gender- and age-specific prevalence of hypothyroidism in Finland.
authors.affiliation: Research Department, The Social Insurance Institution, Turku, Finland.
authors.forename: Lauri J
authors.initials: LJ
authors.lastname: Virta
authors.forename: Seija I
authors.initials: SI
authors.lastname: Eskelinen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D016208:Databases, Factual; D005260:Female; D005387:Finland / Q000453:epidemiology; D020249:Hormone Replacement Therapy; D006801:Humans; D007037:Hypothyroidism / Q000188:drug therapy* / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D010045:Outpatients; D055656:Prescriptions; D013974:Thyroxine / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D013974:Thyroxine
references.citation: Thyroid. 1999 Jul;9(7):735-40
references.pmid: 10447022
references.citation: Eur J Endocrinol. 2000 Nov;143(5):639-47
references.pmid: 11078988
references.citation: Eur J Pediatr. 1984 Nov;143(1):2-5
references.pmid: 6510425
references.citation: Basic Clin Pharmacol Toxicol. 2010 Feb;106(2):86-94
references.pmid: 19961477
references.citation: J Intern Med. 1991 May;229(5):407-13
references.pmid: 2040866
references.citation: Lancet. 2004 Mar 6;363(9411):793-803
references.pmid: 15016491
references.citation: Arch Intern Med. 2000 Feb 28;160(4):526-34
references.pmid: 10695693
references.citation: Cochrane Database Syst Rev. 2007 Jul 18;(3):CD003419
references.pmid: 17636722
references.citation: Age Ageing. 1991 Jul;20(4):291-8
references.pmid: 1927738
references.citation: J Clin Endocrinol Metab. 1990 Sep;71(3):764-9
references.pmid: 2394778
references.citation: Arch Intern Med. 1985 Aug;145(8):1386-8
references.pmid: 4026469
references.citation: JAMA. 2004 Jan 14;291(2):228-38
references.pmid: 14722150
references.citation: N Engl J Med. 1987 Mar 26;316(13):764-70
references.pmid: 3821822
references.citation: J Clin Endocrinol Metab. 1998 Mar;83(3):765-9
references.pmid: 9506723
references.citation: J Clin Endocrinol Metab. 2002 Feb;87(2):489-99
references.pmid: 11836274
references.citation: BMJ. 1993 Oct 2;307(6908):846-8
references.pmid: 8401129
references.citation: Eur J Nucl Med Mol Imaging. 2002 Aug;29 Suppl 2:S404-16
references.pmid: 12192540
references.citation: Clin Endocrinol (Oxf). 2008 Feb;68(2):311-6
references.pmid: 17970771